核糖体生物发生
核仁
核磷蛋白
核糖体
下调和上调
核仁素
细胞生物学
化学
癌症研究
翻译(生物学)
净现值1
激酶
生物
蛋白激酶A
癌症
核蛋白
巴基斯坦卢比
蛋白质生物合成
磷酸化
癌细胞
核糖体蛋白
线粒体
RNA解旋酶A
细胞周期
核糖核酸
线粒体核糖体
肝癌
细胞生长
肝细胞癌
细胞周期蛋白依赖激酶1
生物化学
胞浆
作者
Yu Lu,Lunbiao Gan,Wenxiu Ru,Yujing Guo,Qian Huang,Sha Yin,Fengze Nie,Sijia Di,Siyu Yao,Huanhuan Wan,Fa Yang,Weijun Qin,Weihong Wen
标识
DOI:10.1073/pnas.2535921123
摘要
Liver cancer is the fourth leading cause of global cancer mortality, with hepatocellular carcinoma (HCC) accounting for most primary liver cancers. The nucleolus, as the primary site of ribosome biogenesis, plays a crucial role in HCC development. Here, we report that the nucleolar protein KRR1 interacting protein (KRI1) is aberrantly overexpressed in HCC tissues and interacts with nucleophosmin 1 (NPM1) via phase separation to maintain nucleolar structure and ribosome biogenesis. Downregulation of KRI1 significantly impairs HCC cell proliferation and increases apoptosis, accompanied by disrupted nucleolar structure and ribosome biogenesis. Moreover, we show that KRI1 phase separation is enhanced by the phosphorylation of three serine residues (S94, S95, and S97) in its N-terminal intrinsically disordered region, and pyruvate kinase M2 (PKM2) is identified as the key kinase. PKM2 inhibitor shikonin markedly attenuates KRI1 phase separation and its interaction with NPM1, disrupts nucleolar structure and ribosome biogenesis, thereby inhibiting HCC progression. This study uncovers the crucial role of KRI1 in HCC progression and provides theoretical and experimental evidence for the development of nucleolar protein-targeted therapeutic strategies for HCC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI